Imatinib and Orfadin Suspension
Determining the interaction of Imatinib and Orfadin Suspension and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib. According to the manufacturer, imatinib increased the mean peak plasma concentration (Cmax) and systemic exposure (AUC) of simvastatin, a sensitive CYP450 3A4 substrate, by 2- and 3.5-fold, respectively. Data for other substrates are limited, although human liver microsome studies indicate that imatinib is a potent competitive inhibitor of all three isoenzymes. MANAGEMENT: Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy. References "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR: Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib. According to the manufacturer, imatinib increased the mean peak plasma concentration (Cmax) and systemic exposure (AUC) of simvastatin, a sensitive CYP450 3A4 substrate, by 2- and 3.5-fold, respectively. Data for other substrates are limited, although human liver microsome studies indicate that imatinib is a potent competitive inhibitor of all three isoenzymes.
MANAGEMENT: Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.
- "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: nitisinone
Brand name: Orfadin, Nityr
Synonyms: Orfadin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Imatinib-Orfro
- Imatinib-Orgaran
- Imatinib-Orilissa
- Imatinib-Oritavancin
- Imatinib-Oritavancin Diphosphate
- Imatinib-Oritavancin Intravenous
- Orfadin Suspension-Imatinib Mesylate
- Orfadin Suspension-Imbruvica
- Orfadin Suspension-Imbruvica (Ibrutinib Capsules)
- Orfadin Suspension-Imbruvica (Ibrutinib Tablets)
- Orfadin Suspension-Imdur
- Orfadin Suspension-Imdur ER